SHIRE PLC: Director/PDMR Shareholding

Director/PDMR Share Dealings 
April 1, 2014 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company") announces
that it was notified on March 31, 2014 that on that day Ordinary Shares
("Shares") and American Depository Shares ("ADSs") of the Company, as set out
below, had been awarded under the Shire Executive Annual Incentive Plan
("EAIP") to Persons Discharging Managerial Responsibility ("PDMRs"). The Shares
and ADSs were acquired on March 31, 2014 at prices of £29.8997 per Share and
$147.64 per ADS. 

                                           Type of       Number of     

Flemming Ornskov                            ADSs           2,703        
Tatjana May                                Shares          4,176        
The awards will normally be released to participants after a period of three
years. One ADS is equal to three Shares. 
In addition, the Company was notified on March 31, 2014 of the release of the
following Shares awarded in 2011 under the EAIP. 

                                         Number of    Number of Shares
                                          Shares      sold to satisfy 
                                          released    tax liabilities 

Tatjana May                                4,517                 2,139 
On March 31, 2014 sufficient Shares were sold to satisfy tax liabilities as set
out above. The Shares were sold at a price of £29.8076 per Share. 
The above transactions in Shares and ADSs took place on the London Stock
Exchange and NASDAQ respectively. 
This notification relates to disclosures made in accordance with 3.1.4(R)(1)(a)
of the Disclosure and Transparency Rules. 
Tony Guthrie
Deputy Company Secretary 
For further information please contact: 
Investor Relations                                                              
Laurie Stelzer                   +1 781 482 0733    
Eric Rojas                         +1 781 482 0999    
Sarah Elton-Farr               +44 1256 894157    
Notes to editors 
Shire enables people with life-altering conditions to lead better lives. 
Our strategy is to focus on developing and marketing innovative specialty
medicines to meet significant unmet patient needs. 
We provide treatments in Neuroscience, Rare Diseases, Gastrointestinal and
Internal Medicine and we are developing treatments for symptomatic conditions
treated by specialist physicians in other targeted therapeutic areas. 
Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX 
Press Release                                      
-0- Apr/01/2014 11:00 GMT
Press spacebar to pause and continue. Press esc to stop.